Latest News
2021 HAE Day 🙂
Happy HAE Day and Happy 10th Anniversary! We hope everyone celebrated HAE Day 🙂 by
TAKHZYRO: Available in Saskatchewan
HAE Canada is happy to share that Saskatchewan is the latest province to add lanadelumab
HAEGARDA: Available Across Canada
We are over the moon that our members are telling us that they are excited
TAKHZYRO now available in Newfoundland & Labrador
We love sharing amazing news, and now we have even more to love! On March
April 6 is the day for HAEGARDA in Canada!
We are thrilled to let you know that starting April 6, HAEGARDA, a subcutaneous C1 Esterase
Takhzyro Added to the NIHB Formulary
We are happy to share that eligible HAE patients across Canada who have coverage under
Takhzyro soon available in Manitoba
Great news for eligible HAE patients in Manitoba! Starting April 1, 2021, Manitoba Pharmacare will
Takhzyro is now available in BC
Have you heard the latest fantastic news? British Columbia has recently started providing access to
Ontario is the latest province to provide access to Takhzyro!
We are excited to share that Ontario is the latest province to provide access to
New Brunswick has added TAKHZYRO to their Provincial Drug Plan!
Another province has added TAKHZYRO to their provincial formulary! As of January 27th, 2021, Type
Support Family Testing
Give valuable insights in HAE science
Hereditary Angioedema (HAE) is a hereditary disorder. It is therefore very important to have other family members tested. To help you in this process HAE International has developed two documents for patients. You can download the documents below:
